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Background: Women who are diagnosed with gestational diabetes mellitus (GDM) are at increased risk for
developing prediabetes and type 2 diabetes mellitus (T2DM). To date, there have been few interdisciplinary
interventions that target predominantly ethnic minority low-income women diagnosed with GDM. This paper
describes the rationale, design and methodology of a 2-year, randomized, controlled study being conducted in
North Carolina.
Methods/Design: Using a two-group, repeated measures, experimental design, we will test a 14- week intensive
intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to
prediabetes and T2DM, nutrition and exercise education, coping skills training, physical activity (Phase I), educational
and motivational text messaging and 3 months of continued monthly contact (Phase II). A total of 100 African
American, non-Hispanic white, and bilingual Hispanic women between 22–36 weeks of pregnancy who are
diagnosed with GDM and their infants will be randomized to either the experimental group or the wait-listed
control group. The first aim of the study is to determine the feasibility of the intervention. The second aim of study
is to test the effects of the intervention on maternal outcomes from baseline (22–36 weeks pregnant) to 10 months
postpartum. Primary maternal outcomes will include fasting blood glucose and weight (BMI) from baseline to
10 months postpartum. Secondary maternal outcomes will include clinical, adiposity, health behaviors and self-
efficacy outcomes from baseline to 10 months postpartum. The third aim of the study is to quantify the effects of
the intervention on infant feeding and growth. Infant outcomes will include weight status and breastfeeding from
birth through 10 months of age. Data analysis will include general linear mixed-effects models. Safety endpoints
include adverse event reporting.
Discussion: Findings from this trial may lead to an effective intervention to assist women diagnosed with GDM to
improve maternal glucose homeostasis and weight as well as stabilize infant growth trajectory, reducing the
burden of metabolic disease across two generations.
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Pregnancy is an unrealized window of opportunity for
primary prevention of diabetes. Approximately a third of
women diagnosed with type 2 diabetes (T2DM) have a
history of gestational diabetes mellitus (GDM), defined
as carbohydrate intolerance during pregnancy [1,2].
GDM affects 1 in 20 pregnant women in the U.S. [1,2].
These women are at increased risk of developing GDM
in subsequent pregnancies and of developing T2DM
later in life [1,3-5], with a cumulative incidence as high
as 70% [6]. Infants born to women with GDM have a 2-
fold risk of developing obesity [7] and a greater risk of
developing T2DM than infants born to normoglycemic
women [8,9]. There is strong evidence that lifestyle inter-
ventions can reduce the risk of progression to T2DM by
58% in the general population [6,10-12] and by 55%
among women with a history of GDM [6]. The American
College of Obstetricians and Gynecologists [13] and the
American Diabetes Association [1,2] recommend that
women with GDM be counseled about diet, exercise,
and weight reduction. However, several studies suggest
that the advice is insufficient to change maternal behav-
ior [14-16]. Effective interventions are therefore needed
to improve health-promoting behaviors among women
with a history of GDM. One-on-one lifestyle interven-
tions such as the Diabetes Prevention Program are
costly and did not target pregnant women [17]. How-
ever, group interventions have been found to be both
acceptable and effective in promoting positive preg-
nancy behaviors [18,19]. Studies of women with GDM
have found self-efficacy to be one of the few modifiable
predictors of physical activity [20-22]. A recent study
demonstrated that breastfeeding may reduce risk of pro-
gression to metabolic syndrome by as much as 86% by
utilizing from 400 to 600 calories a day and stabilizing
blood sugar [23].
It is imperative that women diagnosed with GDM de-
crease their BMI to < 25 kg/m2 after the birth of their in-
fant, both to improve metabolic outcomes and to decrease
progression to T2DM later in life [1,2]. Among reproduct-
ive aged women, excessive gestational weight gain is a
consistent predictor of worsening obesity [24,25]. A total
of 40% of normal weight women and 60% of overweight
women exceed the Institute of Medicine (IOM) prenatal
weight gain guidelines [26,27]. Compared with women
who gain within recommended ranges, women who gain
excessively are more likely to be overweight or obese 10 or
more years later [24,28].
These risks are magnified among women with GDM,
because those who are overweight or obese and do not
lose weight postpartum are at increased risk for develop-
ing prediabetes, T2DM, hypertension, hypercholesterol-
emia and cardiovascular disease later in life [1,2]. The
estimated total economic cost of diagnosed diabetes in2012 was $245 billion, a 41% increase from the previous
estimate of $174 billion (in 2007 dollars) [29].
To reduce the risk of progression to T2DM, interven-
tions must counter secular trends in diet and physical ac-
tivity. Nutritional quality has declined with an increased
intake of sugared beverages and high calorie and high fat
foods [27,30,31]. Less than 50% of adults currently eat five
to six servings of vegetables per day [30,32]. Fast food in-
take has increased along with increased caloric intake and
increased weight in adults [33].
Physical activity has decreased and sedentary behavior
has increased both among in adults in the general popula-
tion and among pregnant women [34]. Current physical
activity guidelines for prenatal and postpartum women is
30 minutes on most if not all days of the week [35]. Ap-
proximately 75% of pregnant women do not meet the
recommended levels of daily physical activity [36].
The intervention to be tested in our trial includes a
comprehensive group Nutrition and Exercise Education,
Coping Skills Training (NEST), and exercise intervention
[37-39]. During pregnancy, participants receive a prenatal
session on the benefits of breastfeeding for metabolic con-
trol and infant health [40-46]. At 6 weeks postpartum,
they receive a session on diabetes education, and messages
are reinforced with weekly educational and motivational
text messages from the time of enrollment to completion
of participant’s time in the study.
Theoretical framework for the intervention
The study intervention is based on social cognitive the-
ory [47-50], which posits that learning and practicing a
new behavior enhances self-efficacy. When self-efficacy
is enhanced, the probability that the new behavior will
be maintained increases [47,48,50]. When an individual
cannot effectively solve a problem, their confidence for
dealing with the next problem is decreased [47-50]. Cop-
ing skills training assists mothers in dealing with prob-
lems they encounter as they incorporate new nutrition
and exercise behaviors [47-50]. Our hypothesis is that
cognitive-affective processes [51] will improve in women
who receive breastfeeding, diabetes, nutrition and exer-
cise education, coping skills training, exercise, a home-
based exercise program, and weekly educational and mo-
tivational text messages. We further hypothesize that
these women will increase self-efficacy, improve their
nutrition and exercise behaviors, and manage their
weight. These behavior changes, in turn, will decrease
their risk of progression to T2DM and improve their in-
fants’ outcomes [37-39,47-50].
Aims
The first aim of the study is to determine the feasibility
of the intervention, including its acceptability, and fur-
ther refine intervention materials and study procedures
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data collection). The second aim of study is to test the
effects of the intervention on maternal outcomes from
baseline at 22–36 weeks pregnant (Time 1) to 6 weeks
postpartum (Time 2), 4 months postpartum and com-
pletion of Phase I (Time 3), 7 months postpartum and
completion of Phase II (Time 4), and 10 months post-
partum, after 3 months on their own (Time 5). The pri-
mary maternal outcome is a decrease in fasting blood
glucose and weight from baseline to 10 months postpar-
tum. Secondary maternal outcomes include a decrease
in glucose levels from the oral glucose tolerance test, in-
sulin levels, homeostatic model assessment of insulin re-
sistance (HOMA-IR), glycated hemoglobin A1C (A1C),
lipid panel, blood pressure, and adiposity, as well as im-
provement in health behaviors, eating, exercise and
breastfeeding self-efficacy from baseline to 10 months
postpartum. The third aim of the study is to quantify
the effects of the intervention on infant feeding and
growth outcomes (weight status [weight-for-length]) and
breastfeeding (weeks until stopped breastfeeding, weeks
exclusively breastfed, and intensity of breastfeeding)
from birth to 10 months postpartum.
Methods
Design
The study will use a two-group, randomized, repeated
measures design to test the feasibility of the adapted
NEST intervention for women diagnosed with GDM
during their current pregnancy. See Figure 1. An experi-
mental group of women (n = 50) will receive a two-
phased intervention with follow-up. In Phase I (Intensive
Intervention), interventionists will meet with women in
small groups for 14 sessions. The initial session, during
pregnancy, will focus on the benefits of and strategies
to sustain breastfeeding. The remaining sessions, onRandomization
Experimental Group
N = 50
Phase I Intervention (14 weeks) 
Phase II Intervention (3 months) 
Follow-up (3 months)
Wait-List Control Group
N = 50
Usual Care
Receive Phase I
Classes 2-14 at the completion 
of their time in the study
If they chose
Figure 1 Randomization for the trial.diabetes, nutrition and exercise education, coping skills
training, exercise, and a home-based exercise program,
will start when they are about 6 weeks postpartum. Par-
ticipants will also receive weekly educational and motiv-
ational text messages. In Phase II (Continued Support),
interventionists will hold monthly meetings with the
women for 3 months to discuss problems related to
breastfeeding, nutrition and exercise, and to provide
feedback and support. Data will be collected at baseline
at 22–36 weeks pregnant (Time 1), to 6 weeks postpar-
tum (Time 2), 4 months postpartum and completion of
Phase I (Time 3), 7 months postpartum and completion
of Phase II (Time 4), and 10 months postpartum, after
3 months on their own (Time 5). Time 3 and Time 4
data collections will determine the magnitude of inter-
vention effects after Phase I and Phase II respectively;
Time 5 will determine whether women have maintained
their new skills. Three to 6 months after completion is a
standard length of time for follow-up in weight manage-
ment studies [52].
A wait-list control group (n = 50) will receive usual
care and will have the same data collection schedule as
the experimental group (Time 1-Time 5). After they
complete the Time 5 data collection, they will be offered
sessions 2–14 only.
Settings
The study is being conducted in partnership with the
University of North Carolina at Chapel Hill (UNC-CH)
Schools of Nursing and Medicine and two clinical sites,
Rex Healthcare and WakeMed. Our team has had a
longstanding relationship with both sites. A local church
near Rex Healthcare and a community center near
WakeMed are being utilized for enrollment, data collec-
tion and delivery of the intervention. Women will be en-
rolled during four enrollment periods. After each of the
four enrollment periods, the sites will be randomized to
the experimental or wait-list control group. Women will
be told their group assignment by phone.
Power analysis
Eighty women are expected to complete the study; 40
per group. We will induct 100 women to take into ac-
count a 20% attrition rate seen in our previous studies
[37-39,53]. While individually randomizing women to ei-
ther the experimental or wait-list control group would
be ideal, this is not feasible in our settings because
of the limited number of women with GDM available in
each site during any given enrollment period. Therefore,
we have chosen a cluster-randomized approach. After
a group of women is inducted, they will be randomly
assigned to either the experimental group or the
wait-list control group, to provide a balanced allocation
in each site, yielding a random sequence of two
Table 1 Phase I intensive intervention
Pregnancy
Class 1 The benefits of breastfeeding for metabolic
control and for your infant’s health
Postpartum
Class 2 Reinforcing knowledge about recurrent GDM
and progression to T2DM
Class 3 The importance of daily exercise
Class 4 Understanding calories, proteins, carbohydrates,
and fats
Class 5 How portion control can make a difference
Class 6 How to make healthy substitutes with food
Class 7 Choosing healthy food when eating out
Class 8 Increasing exercise (cognitive restructuring)
Class 9 Improving nutrition and exercise behaviors
(social problem solving)
Class 10 Motivating yourself in a positive manner
(assertiveness training)
Class 11 Understanding barriers to healthy choices
(social problem solving)
Class 12 Getting back on track after relapse
(assertiveness training)
Class 13 Working through conflict (conflict resolution)
Class 14 Putting it all Together
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each site. This will provide two-group, longitudinal com-
parisons of complete data on 40 women per group, for
analyses of changes in metabolic, clinical, weight, adipos-
ity, health behaviors, and self-efficacy at up to four
post-baseline time points. A cluster power calculation
was performed with POWERLIB20 SAS/IML modules,
which incorporate the methods described in Muller [54].
These methods calculate power for the general linear
multivariate model, including repeated measures data,
allowing adjustment for within-cluster correlation, which
is expected to be small. We intend to determine effect
size for each maternal and infant outcome addressed in
Aims 2 and 3 in separate multivariate models. The study
will be well powered to detect moderate to large effect
sizes. An effect size of .67 SD at any post-baseline time
point with this sample size will provide .80 power at the
two-sided .05 significance level; an effect size of .8 SD
increases the power to .92.
Sample
The trial received ethical approval by the Institutional
Review Board at The University of North Carolina at
Chapel Hill, REX Healthcare and WakeMed. Women
between 22–36 weeks of pregnancy who are diagnosed
with GDM are eligible to enroll in the study. Inclusion
criteria include a diagnosis of GDM during the current
pregnancy by two or more 100 g Oral Glucose Tolerance
Test values exceeding established thresholds (fasting 95,
1 h 180, 2 h 155, 3 h 140 mg/dL) [55]; age 18 years or
older; a pre-pregnancy body mass index ≥ 25 kg/m2;
ability to read and write in English; and willingness to
consent for themselves and their infant. Health care pro-
viders will not be asked to give permission for women to
join the study. Women will be excluded if they have an
A1C ≥ 6.5 mg/dL indicating T2DM. The project man-
ager contacted both sites and met with health care
providers and staff to explain the study and distribute
brochures. Any woman diagnosed with GDM who meets
the inclusion criteria is given a brochure and asked to
call the study number. The woman is then screened over
the phone by the project manager. If the woman meets
inclusion criteria and is interested in joining the study,
an enrollment appointment is set up at one of the com-
munity centers at a convenient time for the woman to
confirm eligibility and review the consent. The project
manager confirms eligibility, explains the study, and an-
swers all questions before asking the woman to consent
for herself and her infant.
Phase I intensive intervention
The Phase I classes are adapted from Children and
Parents Partnering Together to Manage their Weight [56]
and the feasibility study Reducing the Risk of ChronicDisease: A Group- Based Weight Loss Program for Post-
partum Mothers [57] with additional sessions about 1)
the importance of breastfeeding for metabolic control
and infant health and 2) reinforcement of GDM reoccur-
rence with future pregnancies, and progression to predi-
abetes and T2DM [37-39,53]; and weekly educational
and motivational text messages until women have com-
pleted their time in the study. Each 60-minute session
will be delivered to a group of 12–13 women (Table 1).
All women at both sites receive a GDM education class
at the time of diagnosis by a certified diabetes educator.
These existing classes are virtually identical. We have
added two classes. We will deliver the first class during
pregnancy, on the benefits of breastfeeding for metabolic
control and for infant health. We will deliver the second
class when women are 6 weeks postpartum to reinforce
knowledge of recurrent GDM and progression to T2DM.
To further support breastfeeding, our interventionists,
who have experience in breastfeeding support, will contact
experimental women weekly until they start classes
(6 weeks postpartum) to inquire how breastfeeding is
progressing and answer questions using a protocol we
have developed with a consultant for our study, based on
an effective pre- and post-natal breastfeeding intervention
protocol [58]. We have a lactation consultant on the grant
that will be available to assist with mother’s breastfeeding
concerns. Also, at each site, registered dietitians will be
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mothers in the experimental group [59].
Beginning with class 2, the women will also participate
in a weekly exercise session for 60 minutes that will in-
clude a 5-minute warm up, 30 minutes of aerobic exer-
cise, a 10-minute cool down, and 15 minutes to go over
the home-based exercise program handout of the week.
Classes will include group walking, zumba dancing, and
cardio kickboxing, which have been well received in our
previous interventions [56,57]. At the end of each ses-
sion 2–14, women will be asked to set a nutrition and
exercise goal for the next week. Women will also receive
an educational or motivational text message weekly from
the time of enrollment until completion of their time in
the study. If a woman is unable to attend a session, the
interventionist will call them and make up class content
over the phone.
Phase II continued support
The experimental group women will then return to the
site for a group session once a month for 3 months.
They will receive a reminder phone call several days be-
fore each session. Women will be weighed and have a
group discussion, run by the interventionist, who will
answer questions and help women problem solve issues
around nutrition, exercise, and breastfeeding. If a
woman misses a session, the interventionist will call and
ask how she is doing. Content will not be made up. The
women will continue to receive monthly educational and
motivational text messages to maintain contact.
Integrity of the intervention
Integrity of the intervention will be assessed by obser-
vation of two randomly selected sessions per month.
The project manager will use a checklist to score ses-
sions based on content identified in the intervention
protocol. Drift will be defined as teaching less than 80%
of the protocol content. If drift occurs, the interven-
tionist will be retrained until the protocol is followed
consistently. We will use a checklist of behavioral indi-
cators to assess the intervener’s skills in facilitating ses-
sions, engaging the women, problem solving, providing
positive feedback, and goal setting. Retraining will be
provided as necessary.
Wait-list control group
Women in the wait-list control group will receive usual
care. Data on the women and infants will be collected at
the same times as on the women and infants in the ex-
perimental group, and women will receive $10 each time
they complete a data collection visit. Wait-list control
group women will receive reminder calls one week be-
fore each visit. Transportation vouchers and childcare
will be provided. During the study, they will receive amonthly card to thank them for their continued partici-
pation. When they have completed the Time 5 data col-
lection, they will be offered the Phase I intervention
(sessions 2–14) classes.
Measurement
Table 2 shows the measures to be used, data sources,
and measurement times. All instruments have been eval-
uated for their psychometric qualities in previous studies
[56,57] and will be reevaluated in this study. Data will be
collected at baseline at 22–36 weeks pregnant (Time 1),
6 weeks postpartum (Time 2), 4 months postpartum and
completion of Phase I (Time 3), 7 months postpartum
and completion of Phase II (Time 4), and 10 months
postpartum, after 3 months on their own (Time 5).
Completion of data collection takes approximately 45
minutes for each mother.
To assess acceptability of the intervention (Aim 1), the
project manager will observe two randomly selected ses-
sions per month to assess whether the sessions are being
taught by the protocol. Participants will be asked to
complete an evaluation at the completion of each ses-
sion. At the Time 5 data collection, a trained research
assistant will conduct a 15-minute exit interview with all
experimental group women. To assess other aspects of
feasibility, the project manager and research assistants
will keep screening and enrollment logs on recruitment
efforts; the number who were ineligible, with reasons for
ineligibility; and the number who declined to participate
with reasons why. The interventionists will keep field
notes and collect data on attendance at each session,
reasons for non-attendance, and number of make-up
sessions provided. To assess the feasibility of the instru-
ments, the research assistants will keep field notes and
collect data on length of time it takes participants to
complete each instrument, challenges encountered, and
the ways they were resolved.
For maternal outcomes (Aim 2), research assistants
blinded to the study group assignment will collect all
data. The research assistants will use a standardized
manual for collecting physiological and questionnaire
data. Prior to each data collection, the research assis-
tants are tested for inter-rater reliability on height,
weight, waist circumference, triceps and subscapular
skinfolds, and weight-for-length measurements.
Metabolic and clinical outcomes
Oral Glucose Tolerance Test (OGTT)
The results of the mothers’ 3-hour OGTT will be copied
from the medical record as Time 1 (baseline) data. The
mother’s 2-hour OGTT will be scheduled through the
outpatient laboratory and laboratory results will be re-
ceived by secure fax from the laboratories. Women diag-
nosed with GDM will have two or more 100 g OGTT
Table 2 Summary of measures
Variables and Their measurement Respondent T1 T2 T3 T4 T5
Aim 1: Feasibility
Process Evaluation Checklist Project Manager X X X
Intervention Session Evaluation Mothers X X X X
Screening and Enrollment logs Project Manager & Research Assistants X
Field Notes Interventionists & Research Assistants X X X X X
Intervention Attendance Interventionists X X X X
Data Collection Attendance Research Assistants X X X X X
Exit Interview Mothers X
Aim 2: Maternal Outcomes
Metabolic and Clinical Outcomes
3 hour Oral Glucose Tolerance Test 1 (FBG) Mothers X
2 hour Oral Glucose Tolerance Test 2 (FBG) Mothers X X
Insulin Level and HOMA-IR Mothers X X X
A1C and Lipid Panel Mothers X X
Blood Pressure Mothers X X X X X
Weight Status Outcomes
Height, Weight, Body Mass Index Mothers X X X X X
Adiposity Outcomes
Waist Circumference Mothers * X X X X
Triceps & Subscapular Skinfolds Mothers X X X X X
Health Behavior Outcomes
Adult Health Behavior Survey Mothers X X X X X
Health Promoting Lifestyle Profile II Mothers X X X X X
Accelerometry for 7 days Mothers X X X X X
Self-Efficacy Outcomes
Eating Self-Efficacy Scale Mothers X X X X X
Exercise Self-Efficacy Scale Mothers X X X X X
Breastfeeding Self-Efficacy Scale Mothers X X X X X
Aim: 3 Infant Feeding and Growth
Weeks until breastfeeding stopped # Mothers X X X X
Weeks exclusively breastfed # Mothers X X X X
Intensity of breastfeeding # Mothers X X X X
Weight-by-Length Z scores Infants X X X X
Demographic Data Mothers X
T1 (Baseline, at 22–36 weeks); T2 (6 weeks postpartum); T3 (4 months postpartum at completion of Phase I); T4 (7 months postpartum at completion of Phase II);
T5 (10 months postpartum, after 3 months on their own); 1 3 hour OGTT performed as part of GDM diagnosis includes fasting, 1, 2, and 3 hour glucose after a
100 g load; 2 2 hour OGTT includes a fasting and 2 hour glucose after a 75 g glucose load; * Not done pregnant; # If a mother stops breastfeeding we will stop
collecting data.
Berry et al. BMC Pregnancy and Childbirth 2013, 13:184 Page 6 of 11
http://www.biomedcentral.com/1471-2393/13/184values exceeding established thresholds: (fasting 95, 1 h
180, 2 h 155, 3 h 140 mg/dL) [55]).
Insulin levels
Insulin will be measured from a fasting sample of
venous blood. Aliquots of plasma will be separated, la-
beled and stored at −80 degrees Celsius. Insulin testing
will be completed at Rex Healthcare and WakeMedlaboratories. Both laboratories use the same radio-
immunoassay kit, which has less than 1% cross-reactivity
with C-peptide and proinsulin. The inter-assay variation
for insulin is 12% and intra-assay cross-reactivity is 11%,
which is well within acceptable levels. These assessments
will allow us to confirm the validity of the HOMA- IR.
Normal values are 5–20 micro units per milliliter while
fasting [1,2].
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The HOMA-IR estimates the steady state of beta cell
functioning and insulin sensitivity [60]. HOMA-IR has
been shown to discriminate across race and ethnic
groups and provides a good approximation of more
complex tests [60]. Fasting glucose and insulin will be
drawn on all study participants by experienced labora-
tory personnel at either Rex Healthcare or WakeMed.
The formula to be used is: (fasting insulin (IU/ml) ×
fasting glucose (mmol/l)/22.5 [60]. Greater HOMA-IR
values indicate reduced insulin sensitivity. A value over
2.2 is indicative of insulin resistance [60].
Glycated hemoglobin (A1C)
A1C is measured using an immunoassay that measures
the concentration of a macromolecule in a solution
through the use of an immunoglobulin. A1C will be
drawn on all study participants by experienced labora-
tory personnel at either Rex Healthcare or Wake Med.
An A1C ≥ 6.5 will be considered a diagnosis of type 2
diabetes [1,2]. and those women will be excluded from
the study and referred to an endocrinologist.
Lipid panel
Total cholesterol, low-density lipoprotein (LDL), high-
density lipoprotein (HDL) and triglycerides will be
drawn and run by experienced laboratory personnel at
either Rex Healthcare or WakeMed. Lipids will be de-
termined by automated methods using the Hitachi 704
Analyzer (Roche Diagnostics). Desirable total choles-
terol levels are below 200 mg/dL in adults. Normal
fasting triglyceride levels are below 150 mg/dL. Desir-
able LDL levels are below 130 mg/dL. A low HDL is
considered to be a value below 35 mg/dL, and high
HDL, ≥60 mg/dL [61].
Blood pressure
Blood pressure will be measured with a Welch Alyn
VSM 300 automatic blood pressure machine (Welch
Alyn). The cuff bladder will cover at least two-thirds of
the upper right arm and at least half of the circumfer-
ence. The participant will sit quietly for 10 minutes prior
to measurement. Blood pressure will be taken twice
with at least 5 minutes between measurements, using
recommended procedures [62,63].
Weight status outcomes
Height will be measured twice and averaged on all
women in street clothes without shoes. A portable
stadiometer will be calibrated to 1/8-centimeter inter-
vals. Weight will be measured twice and averaged in a
private room on all women in street clothes and without
shoes using a Tanita WB-110A Digital Scale. Body mass
index (BMI) of mothers will be calculated twice byentering height and weight (kg/m2) [64,65]. In adults,
overweight will be defined as a BMI between 25.0 to
29.9 kg/m2 and obesity will be defined as above
30.0 kg/m2 [64,65].
Adiposity outcomes
All adiposity measures will be taken in a private room
by two research assistants. All adiposity measurements
will be taken three times and averaged according to the
National Health and Nutrition Examination Survey pro-
cedures [64,65]. Waist circumference will be measured
using a Figure Finder measuring tape with lock (Novel
Products Inc., Rockton, IL). Triceps and subscapular
skinfolds will be measured using Lange skinfold calipers.
Health behavior outcomes
The Adult Health Behavior Survey [66] will be used to
collect information on intake of fruits, vegetables, sug-
ared beverages, water, and fast food. Responses on the
23-item questionnaire will be recorded a 1 for a healthy
behavior and 2 for an unhealthy behavior. Alpha coeffi-
cients in adults have ranged from 0.80 to 0.86 [66].
The Health Promoting Lifestyle Profile II (HPLP II)
will be used to measure health promoting behaviors
[67]. The HPLP II is a 48-item questionnaire that uses a
4-point Likert scale with responses including never,
sometimes, often or routinely. The four subscales used
for this study include health responsibility, exercise, nu-
trition, and stress management. Alpha coefficients have
ranged from 0.78 to 0.93 for the subscales [67].
Accelerometry will be measured for 7 continuous days
using the Computer Sciences and Applications (CSA)
uniaxial accelerometer to capture weekday and weekend
physical activity. Accelerometers do not rely on self-
report and provide an objective measure of physical ac-
tivity [68,69]. Information from the use of accelerometry
assesses the intensity, frequency, and duration of activity
performed [68]. Taking multiple days of CSA measure-
ments and averaging them has been reported to increase
alpha coefficients from 0.42-0.47 for 1 day to 0.7 for
4 days in adults [69,70]. The research assistant will ex-
plain the accelerometer to the mother and review the
procedure. The mother will be provided with a log book
to keep track of her daily activity and a phone number
to call if she needs help. Mothers will be provided with a
mailer to mail the accelerometer back at the end of the
7 days. A research assistant will send out a text message
to the mother in the morning to remind her to put her
accelerometer on.
Self-efficacy outcomes
The Eating Self-Efficacy Scale [71] will be used to meas-
ure dietary self-efficacy. The questionnaire consists of
25-tems and will ask women to rate their difficulty in
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negative affect scale and the socially acceptable scale
with a 1 reflecting no difficulty to a 7 reflecting a high
degree of difficulty. Socially acceptable eating is defined
as overeating at holiday or family events. Negative
affect eating is defined as emotional eating. Alpha coef-
ficients have been found to be 0.85 for the socially ac-
ceptable eating subscale and 0.94 for the negative affect
subscale [71].
Breastfeeding Self-Efficacy will be measured using the
Breast Feeding Self-Efficacy Scale [72]. The 14-item
questionnaire will ask women how sure they are regard-
ing breastfeeding with a 1 reflecting not at all confident
to a 5 reflecting very confident. Alpha coefficients range
from .92 to .96 [72].
Infant outcomes
For infant feeding and growth (Aim 3), we will measure
breastfeeding duration and intensity as a modifiable risk
factor for maternal and infant metabolic disease. We
will define breastfeeding duration as the time since birth,
in weeks, until the mother stops breastfeeding or ex-
pressing milk for her infant. We will define exclusive
breastfeeding as the time, in weeks, until the mother in-
troduces formula or complementary foods. We will de-
fine breastfeeding intensity as the percent of all milk
feeds that are breast milk (# of breast milk feeds per
day) / (# of breast milk + formula + other milk feeds per
day) [73,74]. We will measure weight-for-length in in-
fants, using standardized weight-for-length z scores [75].
Length will be measured twice and averaged using a
portable length board and weight will be measured twice
and averaged using a portable calibrated digital scale
according to procedures.
Demographic data
Women will complete a demographic form, including
questions about age, race/ethnicity, marital status, and
income level.
Procedures
The project manager will call women who have shown an
interest in the study, give a verbal description of the study
and ask pre-pregnancy height and weight. If they meet in-
clusion criteria, the research assistant will schedule an ap-
pointment and meet the woman at the site. The research
assistant will give the woman an oral description of the
study, requirements of participants, and the risks and
benefits of participating; random assignment will be
explained; and all questions will be answered. After in-
formed consent, physiological data will be collected in a
private room at the site. The research assistant will collect
data in the same order each time: height, weight, waist
circumference, triceps and subscapular skinfolds, andquestionnaires, which should take 45 minutes. The 3-hr
OGTT at Time 1 will be abstracted from the medical rec-
ord. Data on infant length-by-weight will be collected fol-
lowing standard procedures.
Data management
Participants will be tracked using ID numbers. All data
will be double entered by different research assistants
into a SAS database and backed up on a secure central
computer network system. Comparisons will be run for
the two versions, and inconsistencies will be checked
against the raw data and corrected. Data will undergo
range, consistency, and outlier checks. An audit trail will
be established to document any changes.
Data analysis
Aim 1
To determine the acceptability of the intervention ses-
sions and materials, the investigators will analyze the in-
terventionists’ field notes and exit interviews with
women, which will be tape-recorded with participants’
permission, transcribed, and analyzed for themes. The
findings will be used to further adapt and refine the
intervention. To assess other aspects of feasibility, re-
cruitment yield will be described by the number
contacted and the number screened required to yield
one enrollment. Interventionists will keep attendance re-
cords for each class. Retention will be described at each
time point. Statistics on data collection, such as duration
of collection per woman, will also be computed at each
time point. Rates of recruited, screened, and retained
women will be presented by group and time point, along
with 95% confidence intervals; the upper bounds will
provide an estimate of worst case values for rates in a fu-
ture study.
Aims 2 and 3
To analyze maternal outcomes, descriptive statistics will
be calculated for each measure at each time point. All
analyses will be conducted using an intention-to-treat
approach. Standardized effect sizes for each measure will
be calculated for each time point as the ratio of the
mean difference between the intervention and wait-list
control group to its standard deviation. Correlation
matrices will be computed to describe the degree of cor-
relation of each measure across the repeated measures
for each group. For the assessment of trends in Aim 2,
preliminary analyses will be conducted to determine
whether, despite randomization, the intervention and
control groups were unbalanced at baseline on any mea-
sured variable. Any such variable will be examined for
statistically significant relationships with any of the out-
come measures, and if any are found, the variable will be
considered as a covariate for subsequent models.
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ate linear mixed-effects model will be constructed. These
will model data across all available post-baseline time
points; contrasts will be constructed to evaluate the effects
of the intervention over the post-baseline period, as com-
pared to the wait-list control group, with covariate adjust-
ment for baseline values. These models will include
assessment for main effects for experimental group, time
point, and site, as well as interactions, and will account for
the within-site and within-subject correlation structure in-
voked via the study design. This approach will provide
useful information in guiding the analysis of a future
study. Least-squares means will be computed and plotted
for each time point for each group to determine average
trajectories for each measure.
Discussion
Optimizing Outcomes in Women with Gestational Dia-
betes Mellitus and their Infants study will provide
insight into the initial efficacy of a 14-week intervention
that focuses on the benefits of breastfeeding, under-
standing GDM and progression to T2DM, nutrition and
exercise education, coping skills training, physical activ-
ity, educational and motivational text messaging and
3 months of continued support. The results of the study
will provide crucial information on feasibility of deliver-
ing the intervention in a hard to reach population. The
extensive measurements on maternal outcomes includ-
ing metabolic and clinical, weight, adiposity, health be-
havior and self-efficacy and infant feeding and growth
outcomes will provide a strong foundation to develop an
efficacy study. This trial may lead to an effective inter-
vention to assist women diagnosed with GDM to im-
prove glucose and weight as well as stabilize infant
growth trajectory, thereby reducing the burden of meta-
bolic decrease across two generations.
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